1
|
Todaka H, Arikawa M, Noguchi T, Ichikawa A, Sato T. Donepezil, an anti-Alzheimer's disease drug, promotes differentiation and regeneration in injured skeletal muscle through the elevation of the expression of myogenic regulatory factors. Eur J Pharmacol 2021; 911:174528. [PMID: 34582845 DOI: 10.1016/j.ejphar.2021.174528] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 09/18/2021] [Accepted: 09/23/2021] [Indexed: 10/20/2022]
Abstract
We previously demonstrated that donepezil, an anti-Alzheimer's disease drug, improved skeletal muscle atrophy by enhancing the angiogenesis of endothelial cells and activating the proliferation of satellite cells in a mouse model of peripheral arterial disease. However, the effect of donepezil on muscle differentiation during regeneration remains unclear. Therefore, we measured the expressions of myogenic regulatory factors and late muscle differentiation markers in donepezil-treated C2C12 myoblast cells before and after the induction of cell differentiation. The results indicate that the expressions of myogenin, troponin T (TnT) and myosin heavy chain (MyHC) were significantly increased and myotube formation was accelerated in donepezil-treated cells under the differentiation condition. However, the promotive effect of donepezil on muscle differentiation could not be reproduced by the addition of acetylcholine (ACh) and was not disrupted after treatment with ACh receptor blockers. Moreover, other kinds of acetylcholinesterase inhibitors failed to promote muscle differentiation in C2C12 cells. These results indicate that the specific characteristics of donepezil in the promotion of muscle differentiation are independent of its acetylcholinesterase-inhibitory action. We further found that donepezil induced an incremental shift of the cross-sectional area of myofibers and elevated the expressions of myogenin, TnT and MyHC in a mouse model of cardiotoxin injury. These results suggest that donepezil promotes the differentiation of muscle regeneration upon injury via the elevation of the expressions of myogenic regulatory factors and late muscle differentiation markers. Our findings suggest that donepezil can be a useful therapeutic agent for injured skeletal muscle treatment.
Collapse
Affiliation(s)
- Hiroshi Todaka
- Department of Cardiovascular Control, Kochi Medical School, Nankoku, Kochi, Japan.
| | - Mikihiko Arikawa
- Department of Biological Sciences, Faculty of Science and Technology, Kochi University, Akebono, Kochi, Japan
| | - Tatsuya Noguchi
- Department of Cardiology and Geriatrics, Kochi Medical School, Nankoku, Kochi, Japan
| | - Atsushi Ichikawa
- Department of Cardiovascular Control, Kochi Medical School, Nankoku, Kochi, Japan
| | - Takayuki Sato
- Department of Cardiovascular Control, Kochi Medical School, Nankoku, Kochi, Japan
| |
Collapse
|
2
|
Tsiaoussis J, Hatzidaki E, Docea AO, Nikolouzakis TK, Petrakis D, Burykina T, Mamoulakis C, Makrigiannakis A, Tsatsakis A. Molecular and clinical aspects of embryotoxicity induced by acetylcholinesterase inhibitors. Toxicology 2018; 409:137-143. [PMID: 30055296 DOI: 10.1016/j.tox.2018.07.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 07/23/2018] [Accepted: 07/24/2018] [Indexed: 12/20/2022]
Abstract
Acetylcholinesterase inhibitors are widely used for a variety of medical, agricultural and public health purposes. Consequently, exposure is highly possible during lifetime. However, their systematic use raises concerns for the potential impact on the fetus and newborn since these substances may affect angiogenesis, the neonatal and maternal intensive care, neuroimmune function and response, mammary growth/lactation via cholinergic/non-cholinergic central and peripheral neuroendocrine pathways. New methodologies, neuroscientific technologies and research studies are needed to harness existing knowledge along with the proper management, availability for new acetylcholinesterase inhibitors, with stable pharmacodynamics and clinical outcomes.
Collapse
Affiliation(s)
- J Tsiaoussis
- Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, Voutes, 71110, Heraklion, Crete, Greece.
| | - E Hatzidaki
- Department of Neonatology, University of Crete, Voutes, 71110, Heraklion, Crete, Greece.
| | - A O Docea
- Department of Toxicology, University of Medicine and Pharmacy, Faculty of Pharmacy, Craiova, 200349, Romania.
| | - T K Nikolouzakis
- Laboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, Voutes, 71110, Heraklion, Crete, Greece.
| | - D Petrakis
- Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Voutes, 71003, Heraklion, Crete, Greece.
| | - T Burykina
- Department of Analytical and Forensic Medical Chemistry, Sechenov University, 119991, Moscow, Russian Federation
| | - C Mamoulakis
- Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, 71003, Heraklion, Crete, Greece.
| | - A Makrigiannakis
- Department of Obstetrics and Gynecology, Medical School, University of Crete, 71003, Heraklion, Crete, Greece.
| | - A Tsatsakis
- Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Voutes, 71003, Heraklion, Crete, Greece.
| |
Collapse
|
3
|
Nicotinic receptor-dependent and -independent effects of galantamine, an acetylcholinesterase inhibitor, on the non-neuronal acetylcholine system in C2C12 cells. Int Immunopharmacol 2015; 29:31-5. [PMID: 25979761 DOI: 10.1016/j.intimp.2015.04.057] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 04/28/2015] [Accepted: 04/29/2015] [Indexed: 01/08/2023]
Abstract
We previously reported that satellite cells possess the ability to produce angiogenic factors, including fibroblast growth factor (FGF)-2 and vascular endothelial growth factor (VEGF) in vivo. However, whether C2C12 cells possess a non-neuronal cholinergic system (NNCS) or non-neuronal ACh (NNA) remains to be studied; therefore, we investigated the system using C2C12 cells and its regulatory mechanisms. C2C12 cells synthesized ACh, the level of which was comparable with that of cardiomyocytes, and the synthesis was augmented by the acetylcholinesterase inhibitor galantamine. The ChAT promoter activity was upregulated by nicotine or galantamine, partly through nicotinic receptors for both agents as well as through a non-nicotinic receptor pathway for galantamine. Further, VEGF secretion by C2C12 cells was also increased by nicotine or galantamine through nicotinic receptors as well as partly through non-nicotinic pathways in the case of galantamine. These results suggest that C2C12 cells are equipped with NNCS or NNA, which is positively regulated through nicotinic or non-nicotinic pathways, particularly in the case of galantamine. These results provide a novel concept that myogenic cells expressing NNA can be a therapeutic target for regulating angiogenic factor synthesis.
Collapse
|